
Argenx discontinues Phase III Sjögren’s disease trial
argenx has revealed that it will discontinue the Phase III UNITY study of Vyvgart Hytrulo (efgartigimod subcutaneous – efgartigimod alfa and hyaluronidase-qvfc) in adults with moderate-to-severe Sjögren’s disease. The company said the decision is based on the recommendation from an Independent Data Monitoring Committee (IDMC) to stop… Read More




